미국의 오피스 기반 랩 시장 규모, 점유율, 동향 분석 : 모달리티별, 서비스별, 전문의별, 부문별 예측(2025-2033년)

U.S. Office-based Labs Market Summary

The U.S. office-based labs market size was estimated at USD 13.90 billion in 2024 and is expected to reach an estimated value of USD 35.21 billion by 2033, growing at a CAGR of 11.16% from 2025 to 2033. Growing preference for office-based labs by patients in the U.S. in recent years and the increasing trend of performing surgical interventions in outpatient settings are among key factors driving the market growth. Office-based labs (OBLs) are playing a vital role in transforming the healthcare delivery system and are supporting the growth of medical devices, equipment, and other products.The rapidly transitioning healthcare delivery scenario is driving key market players to transform their business models to achieve maximum benefit from ongoing transition.

The rising number of cardiovascular and radiological procedures in the U.S. is a significant growth driver for the office-based labs (OBLs) market. Cardiovascular disease remains the leading cause of death in the U.S. A report from the 2024 Heart Disease and Stroke Statistics indicates that nearly half of the U.S. population (48.6%) has some form of cardiovascular disease, including coronary heart disease, heart failure, stroke, and high blood pressure. This growing disease burden is translating into an increased demand for diagnostic and interventional procedures, thereby supplementing market growth.

Peripheral artery disease in particular is fueling demand for outpatient interventional care. According to the American Heart Association report published in 2022, peripheral artery disease (PAD) affected approximately 8.5 million people aged 40 and in the U.S. Peripheral artery disease often requires minimally invasive vascular interventions, such as angioplasty, atherectomy, or stenting, which are increasingly being performed in outpatient settings.

U.S. Office-based Labs Market Report Segmentation

This report forecasts revenue growth at the country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. office-based labs market report based on service, modality, and specialist:

• Services Outlook (Revenue, USD Million, 2021 - 2033)
• Peripheral Vascular Intervention
  • Atherectomy
  • Vascular Angioplasty
  • Stenting
  • Other PVI
• Endovascular Interventions
• Cardiac
• Interventional radiology
  • Uterine Fibroid Embolization (UFE)
  • Prostate Artery Embolization (PAE)
  • Y90/Oncology
  • Other IR
• Venous
  • RFA (Radiofrequency Ablation) and EVLT (Endovenous Laser Therapy)
  • Sclerotherapy/Glue
  • Venous Stenting
  • Other Deep Vein
• Others
• Services Outlook (Number of Procedures, 2021 - 2033)
• Peripheral Vascular Intervention
  • Atherectomy
  • Vascular Angioplasty
  • Stenting
  • Other PVI
• Endovascular Interventions
• Cardiac
• Interventional radiology
  • Uterine Fibroid Embolization (UFE)
  • Prostate Artery Embolization (PAE)
  • Y90/Oncology
  • Other IR
• Venous
  • RFA (Radiofrequency Ablation) and EVLT (Endovenous Laser Therapy)
  • Sclerotherapy/Glue
  • Venous Stenting
  • Other Deep Vein
• Others
• Modality Outlook (Revenue, USD Million, 2021 - 2033)
• Single Specialty
• Multi-Specialty
• Hybrid
• Specialist Outlook (Revenue, USD Million, 2021 - 2033)
• Vascular Surgeons
• Interventional Cardiologists
• Interventional Radiologists
• Others

Chapter 01 Methodology And Scope

• 1.1 Market Segmentation & Scope
• 1.2 Segment Definitions
  • 1.2.1 Estimates And Forecast Timeline
• 1.3 Research Methodology
  • 1.3.1 Information Procurement
    • 1.3.1.1 Purchased Database
  • 1.3.2 Gvr's Internal Database
    • 1.3.2.1 Secondary Sources
    • 1.3.2.2 Primary Research
• 1.4 Information Or Data Analysis
  • 1.4.1 Data Analysis Models
• 1.5 Market Formulation & Validation
• 1.6 Model Details
  • 1.6.1 Three Pillars Of Market Estimation
    • 1.6.1.1 Secondary Market Research
    • 1.6.1.2 Primary Market Intelligence
      • 1.6.1.2.1. In-Depth Interviews (Idis)
      • 1.6.1.2.2. Online Survey Program
  • 1.6.2 Market Modeling & Forecasting
    • 1.6.2.1 Procedure Volume Estimation (2021-2024)
    • 1.6.2.2 Average Cost Estimation (2021-2024)
    • 1.6.2.3 Forecasting (2025-2033)
    • 1.6.2.4 Segment Share Analysis
• 1.7 List Of Secondary Sources
• 1.8 List Of Abbreviations
• 1.9 Objectives
  • 1.9.1 Objective - 1
  • 1.9.2 Objective - 2
  • 1.9.3 Objective - 3

Chapter 02 Executive Summary

• 2.1 Market Snapshot
• 2.2 Market Segmentation
• 2.3 Market Segmentation
• 2.4 Competitive Landscape

Chapter 03 Market Variables, Trends & Scope

• 3.1 Market Lineage Outlook
  • 3.1.1 Parent Market Outlook
  • 3.1.2 Ancillary Market Outlook
• 3.2 Market Dynamics
  • 3.2.1 Market Driver Analysis
    • 3.2.1.1 Increasing Volume Of Cardiovascular And Radiological Procedures
      • 3.2.1.1.1. Case Study: Peripheral Vascular Interventions For Peripheral Artery Disease (Pad) In Office-Based Labs
    • 3.2.1.2 Growing Preference For Office-Based Labs Over Hospitals
      • 3.2.1.2.1. Case Study: Trends In Peripheral Vascular Interventions And The Rise Of Office-Based Laboratories In The U.S.
      • 3.2.1.2.2. Case Study: Utilization Patterns And Outcomes Of Pad Procedures In Office-Based Labs Versus Hospitals.
    • 3.2.1.3 Advancing Technology And Rising Preference For Minimally Invasive Procedures
  • 3.2.2 Market Restraint Analysis
    • 3.2.2.1 High Risk Option For Severe Cases
    • 3.2.2.2 High Capital Investment And Operational Costs
  • 3.2.3 Market Opportunity Analysis
    • 3.2.3.1 Strategic Partnerships And Physician Ownership
  • 3.2.4 Market Challenges Analysis
    • 3.2.4.1 Competitive Pressure From Ambulatory Surgical Centers (Ascs) And Hospital Outpatient Departments (Hopds)
• 3.3 Regulatory Framework & Reimbursement Scenario
  • 3.3.1 Regulatory Framework
  • 3.3.2 Reimbursement Scenario
• 3.4 Business Environment Analysis Tools
  • 3.4.1 Porter's Five Forces Analysis
  • 3.4.2 Pestle Analysis

Chapter 04 U.S. Office-Based Labs Market: Modality Estimates & Trend Analysis

• 4.1 U.S. Office-Based Labs Market: Modality Movement Share Analysis, 2024 & 2033
• 4.2 U.S. Office-Based Labs Market: Modality Segment Dashboard
• 4.3 U.S. Office-Based Labs Market Size & Forecast And Forecasts, By Modality (Usd Billion)
  • 4.3.1 Single Specialty Labs
    • 4.3.1.1 Single Specialty Labs Market, 2021 - 2033 (Usd Billion)
  • 4.3.2 Multi-Specialty Labs
    • 4.3.2.1 Multi-Specialty Labs Market, 2021 - 2033 (Usd Billion)
  • 4.3.3 Hybrid Labs
    • 4.3.3.1 Hybrid Labs Market, 2021 - 2033 (Usd Billion)

Chapter 05 U.S. Office-Based Labs Market: Service Estimates & Trend Analysis

• 5.1 U.S. Office-Based Labs Market: Service Movement Share Analysis, 2024 & 2033
• 5.2 U.S. Office-Based Labs Market: Service Segment Dashboard
• 5.3 U.S. Office-Based Labs Market Size & Forecast And Forecasts, By Service (Usd Billion)
  • 5.3.1 Peripheral Vascular Intervention
    • 5.3.1.1 Reimbursement Scenario
    • 5.3.1.2 Peripheral Vascular Intervention Market, 2021 - 2033 (Usd Billion)
    • 5.3.1.3 Peripheral Vascular Intervention Procedure Volume Estimates & Forecasts, 2021 - 2033 (Units)
    • 5.3.1.4 Atherectomy
      • 5.3.1.4.1 Atherectomy Market, 2021 - 2033 (Usd Billion)
      • 5.3.1.4.2 Atherectomy Procedure Volume Estimates & Forecasts, 2021 - 2033 (Units)
    • 5.3.1.5 Vascular Angioplasty
      • 5.3.1.5.1 Vascular Angioplasty Market, 2021 - 2033 (Usd Billion)
      • 5.3.1.5.2 Vascular Angioplasty Procedure Volume Estimates & Forecasts, 2021 - 2033 (Units)
    • 5.3.1.6 Stenting
      • 5.3.1.6.1 Stenting Market, 2021 - 2033 (Usd Billion)
      • 5.3.1.6.2 Stenting Procedure Volume Estimates & Forecasts, 2021 - 2033 (Units)
    • 5.3.1.7 Other Pvi
      • 5.3.1.7.1 Other Pvi Market, 2021 - 2033 (Usd Billion)
      • 5.3.1.7.2 Other Pvi Procedure Volume Estimates & Forecasts, 2021 - 2033 (Units)
  • 5.3.2 Cardiac
    • 5.3.2.1 Reimbursement Scenario
    • 5.3.2.2 Cardiac Market, 2021 - 2033 (Usd Billion)
    • 5.3.2.3 Cardiac Procedure Volume Estimates & Forecasts, 2021 - 2033 (Units)
  • 5.3.3 Interventional Radiology
    • 5.3.3.1 Reimbursement Scenario
    • 5.3.3.2 Interventional Radiology Market, 2021 - 2033 (Usd Billion)
    • 5.3.3.3 Interventional Radiology Procedure Volume Estimates & Forecasts, 2021 - 2033 (Units)
    • 5.3.3.4 Uterine Fibroid Embolization (Ufe)
      • 5.3.3.4.1 Uterine Fibroid Embolization (Ufe) Market, 2021 - 2033 (Usd Billion)
      • 5.3.3.4.2 Uterine Fibroid Embolization (Ufe) Procedure Volume Estimates & Forecasts, 2021 - 2033 (Units)
    • 5.3.3.5 Prostate Artery Embolization (Pae)
      • 5.3.3.5.1 Prostate Artery Embolization (Pae) Market, 2021 - 2033 (Usd Billion)
      • 5.3.3.5.2 Prostate Artery Embolization (Pae) Procedure Volume Estimates & Forecasts, 2021 - 2033 (Units)
    • 5.3.3.6 Y90/Oncology
      • 5.3.3.6.1 Y90/Oncology Market, 2021 - 2033 (Usd Billion)
      • 5.3.3.6.2 Y90/Oncology Procedure Volume Estimates & Forecasts, 2021 - 2033 (Units)
    • 5.3.3.7 Other Ir
      • 5.3.3.7.1 Other Ir Market, 2021 - 2033 (Usd Billion)
      • 5.3.3.7.2 Other Ir Procedure Volume Estimates & Forecasts, 2021 - 2033 (Units)
  • 5.3.4 Venous
    • 5.3.4.1 Reimbursement Scenario
    • 5.3.4.2 Venous Market, 2021 - 2033 (Usd Million)
    • 5.3.4.3 Venous Procedure Volume Estimates & Forecasts, 2021 - 2033 (Units)
    • 5.3.3.4 Rfa (Radiofrequency Ablation) And Evlt (Endovenous Laser Therapy)
      • 5.3.3.4.1 Rfa (Radiofrequency Ablation) And Evlt (Endovenous Laser Therapy) Market, 2021 - 2033 (Usd Billion)
      • 5.3.3.4.2 Urfa (Radiofrequency Ablation) And Evlt (Endovenous Laser Therapy) Procedure Volume Estimates & Forecasts, 2021 - 2033 (Units)
    • 5.3.3.5 Sclerotherapy/Glue
      • 5.3.3.5.1 Sclerotherapy/Glue Market, 2021 - 2033 (Usd Billion)
      • 5.3.3.5.2 Sclerotherapy/Glue Procedure Volume Estimates & Forecasts, 2021 - 2033 (Units)
    • 5.3.3.6 Venous Stenting
      • 5.3.3.6.1 Venous Stenting Market, 2021 - 2033 (Usd Billion)
      • 5.3.3.6.2 Venous Stenting Procedure Volume Estimates & Forecasts, 2021 - 2033 (Units)
    • 5.3.3.7 Other Deep Vein
      • 5.3.3.7.1 Other Deep Vein Market, 2021 - 2033 (Usd Billion)
      • 5.3.3.7.2 Other Deep Vein Procedure Volume Estimates & Forecasts, 2021 - 2033 (Units)
  • 5.3.5 Endovascular Interventions
    • 5.3.5.1 Reimbursement Scenario
    • 5.3.5.2 Endovascular Interventions Market, 2021 - 2033 (Usd Million)
    • 5.3.5.3 Endovascular Interventions Procedure Volume Estimates & Forecasts, 2021 - 2033 (Units)
  • 5.3.6 Others
    • 5.3.6.1 Reimbursement Scenario
    • 5.3.6.2 Other Services Market, 2021 - 2033 (Usd Million)
    • 5.3.6.3 Other Services Procedure Volume Estimates & Forecasts, 2021 - 2033 (Units)

Chapter 06 U.S. Office-Based Labs Market: Specialist Estimates & Trend Analysis

• 6.1 U.S. Office-Based Labs Market: Specialist Movement Share Analysis, 2024 & 2033
• 6.2 U.S. Office-Based Labs Market: Specialist Segment Dashboard
• 6.3 U.S. Office-Based Labs Market Size & Forecast And Forecasts, By Specialist (Usd Billion)
  • 6.3.1 Vascular Surgeons
    • 6.3.1.1 Vascular Surgeons Market, 2021 - 2033 (Usd Billion)
  • 6.3.2 Interventional Cardiologists
    • 6.3.2.1 Interventional Cardiologists Market, 2021 - 2033 (Usd Billion)
  • 6.3.3 Interventional Radiologists
    • 6.3.3.1 Interventional Radiologists Market, 2021 - 2033 (Usd Billion)
  • 6.3.4 Other Specialists
    • 6.3.4.1 Other Specialists Market, 2021 - 2033 (Usd Billion)

Chapter 07 U.S. Office-Based Labs Market: Competitive Landscape

• 7.1 Suppliers' Competition Categorization
• 7.2 Service Providers' Competition Categorization
  • 7.2.1 Company Market Position Analysis: Suppliers
  • 7.2.2 Company Market Position Analysis: Service Provider
• 7.3 Strategy Mapping
  • 7.3.1 New Launch And Approval
  • 7.3.2 Acquisition
  • 7.3.3 Partnership & Collaboration
  • 7.3.4 Others
• 7.4 Company Profiles
  • 7.3.1 Koninklijke Philips N.V.
    • 7.3.1.1 Company Overview
    • 7.3.1.2 Financial Performance
    • 7.3.1.3 Product/Service Benchmarking
    • 7.3.1.4 Strategic Initiatives
  • 7.3.2 Ge Healthcare
    • 7.3.2.1 Company Overview
    • 7.3.2.2 Financial Performance
    • 7.3.2.3 Product/Service Benchmarking
    • 7.3.2.4 Strategic Initiatives
  • 7.3.3 Siemens Healthineers Ag
    • 7.3.3.1 Company Overview
    • 7.3.3.2 Financial Performance
    • 7.3.3.3 Product/Service Benchmarking
    • 7.3.3.4 Strategic Initiatives
  • 7.3.4 Medtronic Plc
    • 7.3.4.1 Company Overview
    • 7.3.4.2 Financial Performance
    • 7.3.4.3 Product/Service Benchmarking
    • 7.3.4.4 Strategic Initiatives
  • 7.3.5 Boston Scientific Corporation
    • 7.3.5.1 Company Overview
    • 7.3.5.2 Financial Performance
    • 7.3.5.3 Product/Service Benchmarking
    • 7.3.5.4 Strategic Initiatives
  • 7.3.6 Abbott
    • 7.3.6.1 Company Overview
    • 7.3.6.2 Financial Performance
    • 7.3.6.3 Product/Service Benchmarking
    • 7.3.6.4 Strategic Initiatives
  • 7.3.7 Envision Healthcare Corporation (Kkr)
    • 7.3.7.1 Company Overview
    • 7.3.7.2 Financial Performance
    • 7.3.7.3 Product/Service Benchmarking
    • 7.3.7.4 Strategic Initiatives
  • 7.3.8 Surgical Care Affiliates (Sca)
    • 7.3.8.1 Company Overview
    • 7.3.8.2 Financial Performance
    • 7.3.8.3 Product/Service Benchmarking
    • 7.3.8.4 Strategic Initiatives
  • 7.3.9 Surgery Partners
    • 7.3.9.1 Company Overview
    • 7.3.9.2 Financial Performance
    • 7.3.9.3 Product/Service Benchmarking
    • 7.3.9.4 Strategic Initiatives
  • 7.3.10 Cardiovascular Coalition
    • 7.3.10.1 Company Overview
    • 7.3.10.2 Financial Performance
    • 7.3.10.3 Product/Service Benchmarking
    • 7.3.10.4 Strategic Initiatives
  • 7.3.11 Th Medical
    • 7.3.11.1 Company Overview
    • 7.3.11.2 Financial Performance
    • 7.3.11.3 Product/Service Benchmarking
    • 7.3.11.4 Strategic Initiatives
  • 7.3.12 Vascular Care Group
    • 7.3.12.1 Company Overview
    • 7.3.12.2 Financial Performance
    • 7.3.12.3 Product/Service Benchmarking
    • 7.3.12.4 Strategic Initiatives
  • 7.3.13 Coastal Vascular Institute
    • 7.3.13.1 Company Overview
    • 7.3.13.2 Financial Performance
    • 7.3.13.3 Product/Service Benchmarking
    • 7.3.14.4 Strategic Initiatives